Discover hundreds of clinical trials for virtually all types of cancer
Data from our studies and trials improve cancer treatments nationwide.
Every new cancer medication and treatment starts as an idea conceived in a research laboratory. Our team of more than 100 PhDs and doctors across 16 clinical and research departments are on a mission to discover, collaborate on, and apply new cancer-fighting medications and techniques.
In 2015, we received more than $21 million in externally funded cancer research. We’re using those dollars to make significant advances in several areas, including research in treatment and prevention of prostate cancer, brain cancer, and gynecologic cancers. We’re also studying radiation oncology, radiology, and population health.
Cancer research programs
Our cancer researchers work in six programs:
- Cancer Epidemiology Prevention and Control, which includes collaborative, multi-institutional research that addresses the entire cancer continuum, from the prevention, screening, diagnosis and treatment to long-term outcomes of cancer.
- Cancer Imaging, which brings together expertise in clinical and basic research imaging to improve the identification, diagnosis, and treatment of tumors.
- Developmental Therapeutics, which incorporates two closely related disciplines: experimental therapeutics and clinical therapeutics. Clinical therapeutics is focused on translating an experimental finding into human cancer trials. The need for new and effective anticancer drugs is critical. The overall goal of this program is first drug discovery and then the development of new anticancer drugs with solid tumor selectivity from lead extracts.
- Neuro-Oncology, which includes a strong translational research program that is supported by the country's second largest brain tumor tissue bank. Henry Ford is a leader in the understanding of the genetics of brain tumors, and in the development of therapies matched to each patient's brain tumor genetics for the best chance at recovery. We are a major contributor to The Cancer Genome Atlas (TCGA), a national cooperative of major academic medical centers sponsored by the National Institutes of Health, which is responsible for identifying certain survival-related genes.
- Urologic Oncology, which is built on close interactions between basic scientists and practicing clinicians. The programs benefit from the prostate tissue biorepository of more than 10,000 vials of cancerous and adjacent normal prostate tissue specimens.
- Radiation Oncology, where our researchers work to improve standard methods for giving radiation therapy to patients with cancer and other diseases. These studies are funded by the National Cancer Institute, the Radiation Therapy Oncology Group, and other prominent oncology organizations.
Within these programs, we focus on identifying cancer risk factors and prevention measures, as well as identifying what causes tumors to grow and spread. We study patterns (epidemiology) and behaviors of cancer cells and genes, and we test our findings in local and national clinical trials. Our researchers and doctors work together to translate data from these studies into effective cancer treatments.